Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. - Wikidata - wikimedia - TriplyDB

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

http://www.wikidata.org/entity/Q34718822

about

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease DPP4 in Diabetes Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity Promising therapies for treatment of nonalcoholic steatohepatitis.Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Dietary combination of sucrose and linoleic acid causes skeletal muscle metabolic abnormalities in Zucker fatty rats through specific modification of fatty acid composition.Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration.The pathophysiology of hypertension in patients with obesity.Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.Effect of vildagliptin on hepatic steatosis.Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function.Inhibitory effects of Doenjang, Korean traditional fermented soybean paste, on oxidative stress and inflammation in adipose tissue of mice fed a high-fat diet.Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid.Differentiation of human adipocytes at physiological oxygen levels results in increased adiponectin secretion and isoproterenol-stimulated lipolysis.Dipeptidyl peptidase-4: a key player in chronic liver disease.DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Innate immune activation in obesity.Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.Cardiovascular effects of the DPP-4 inhibitors.

P2860

Q26778329-22434025-23C9-4002-A3F6-7FDE92A7D73D Q26784211-7E09B516-EEAF-449F-B152-8BB7284431BE Q26797335-C45E3C88-D1E0-4588-834F-6C26CBCB1644 Q26800894-12038B08-E63D-4173-9110-23B1BFE15692 Q27006992-1DAD9024-2C17-46EC-91EA-6E8CEB15B803 Q27011819-0F99976D-322A-4E21-9B48-B1C2189B86D2 Q28728101-930F7497-75BF-4772-8133-61A3FA658786 Q30248578-B260DEFC-744B-40CF-B817-7A0CAEC8CF97 Q30717371-05176C67-A8CB-4B80-B07F-CA38472550B7 Q33603296-7A6F0A11-5561-4A9A-B971-3AF2327497C1 Q33603384-ABF1EC7D-AC84-4F79-B446-AF674ED9B96A Q33610654-A39756BC-C08A-450B-9104-714A32868319 Q33802278-BCB64F7F-931B-4472-BD79-38A5435123E1 Q33832051-71E886C8-B82C-4E22-9FAF-B28BFA09BCDE Q33970970-FFDA150C-BA97-421D-96BD-FD8D52920D9A Q34062829-35D30BBD-A898-4205-B774-E3C41F3A7667 Q34647400-8359402F-8229-447C-B699-BCC6B6AA404B Q34733928-558B36C8-D8EC-4A8B-B740-CB1C0F8A9897 Q34746178-DD3A7D62-56EE-4382-9D4A-4BCFBA059310 Q35021492-38716576-D790-441F-81FA-0F78445FEE91 Q35192176-8FB19808-4799-4E8F-A4C0-A9E1B2E5F958 Q35285238-11B76B1B-8339-41F7-A1AC-6E01B0118932 Q35413944-CAA094EE-A27E-439C-A95D-480B689F09C2 Q35442079-357207ED-02F7-48B2-B672-F433B2615539 Q35630861-89B6A3D6-943E-4FF8-8A35-D0B8E8A3F540 Q35696782-A69218CF-261F-4CA3-9421-8E2A8E56F374 Q36170755-FF6C55B3-B887-403D-9A3D-49499D9686F7 Q36254518-3C257F20-A1D4-4A98-BAEB-6A35EB28ADA4 Q36465496-2FB4CB4B-977E-40AE-94F3-BA19A3DB8DF2 Q36639293-56FAFE32-CAF7-47B6-A99F-4E70A1DA3E2D Q36719115-E5C47CB2-5BAB-45ED-8C3A-5CB2B7D2D7F6 Q36783164-B36A4C48-B408-4995-BE3E-6100BCED353F Q37095161-10D090F6-9E41-43D6-BCE5-45436562AAEF Q37258157-DA50DCFE-BB68-4449-8E2C-CBAE43F7778D Q37331331-BBE3056E-A3C6-4374-844F-63E5828EFDDB Q37375539-DB096F50-E2F8-4292-8B95-071E9D7CDE6F Q37466096-283AC3D3-28C5-465A-AD3B-40DC3807CAB2 Q37563114-2E6F777D-C61D-4804-AEFA-CB81E7A7AFAD Q37943719-8062A59F-75AE-4DB0-807A-D402E2672833 Q37984287-D2243E1B-7E0D-4E03-9186-9EF7C7573E7F

P2860

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

http://www.wikidata.org/entity/Q34718822

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@ast

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@en

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@nl

type

label

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@ast

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@en

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@nl

prefLabel

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@ast

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@en

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@nl

P1433

Q34718822-E2A7F687-ECA0-4A3E-B6C1-AA9326EA3E15

P1476

Q34718822-6F122007-ECFA-4A11-A338-A6327CBF826E

P2093

Q34718822-2CEAE7C8-E033-4BD5-A631-8A2582F3EF37

Q34718822-2F263109-FD4A-464D-A01B-1ADD86DC1E85

Q34718822-3DD1C786-63DC-4354-8CE8-B24C7809C7E7

Q34718822-3EA42A1C-6523-4833-982C-BDC2CFF973D7

Q34718822-51323E59-2F13-415D-B117-AF856365B3C0

Q34718822-8583BFF4-5947-4634-9410-C8506C31B055

Q34718822-8AFA0899-2BDF-470C-B708-7A9F6120B466

Q34718822-9047DF0E-9F6A-49AC-941F-3D12303778EE

Q34718822-99D7EBA7-8A13-415F-A65F-923711F07F57

Q34718822-A0CB9975-DE77-46F0-864A-C373FC9BC459

P2860

Q34718822-042EAD47-5514-469C-BAE3-2FB88BE8FF30

Q34718822-056539DA-081A-48E4-8DC3-805D900AFB7A

Q34718822-05A96E6D-44D5-4D64-B89A-768F0D865D5F

Q34718822-07DF7F5D-5A8A-4E51-ACA1-3D726CA4E301

Q34718822-0C95FD0E-914C-4018-B5FF-1B3131989E81

Q34718822-0F233F35-1FDB-4C71-966B-3C9C9273574C

Q34718822-1186CAFE-81BF-4860-BCEA-7FC47911BE58

Q34718822-146C3FEF-FD1D-4F3A-BA77-FC376E06BF74

Q34718822-19AE496C-4730-499B-BBE1-CA3F245F9932

Q34718822-1D44972A-3985-45F9-9530-7461BB8B64D2

P304

Q34718822-9C1B3E0E-C477-4222-B134-DB9B3CF3BE20

P31

Q34718822-3E501DC4-8B3C-419F-816C-2E5EDE403F53

P356

Q34718822-96444EA7-7E27-4C2E-8964-54A535E0213F

P407

Q34718822-909D7209-CFA0-46E6-80E6-F405B75F8D6D

P433

Q34718822-15C1DCE1-5BD4-4E8C-8B58-D6D90ACD23A4

P478

Q34718822-01D218EB-3650-4584-A37F-F5B92DF1B90E

P577

Q34718822-8CDAFD38-A6C8-4C7A-8525-158816707A46

P5875

Q34718822-2E7346BA-98B7-4668-9CB5-D453945DC8B2

P698

Q34718822-8CFE1CB8-288C-4696-A2FA-C0A26D42B4BA

P932

Q34718822-3E666ECA-75ED-4DCF-8359-9040958A0387

P356

P1433

P1476

Diet-induced adipose tissue in ...... 4 inhibition in diabetic mice.

@en

P2093

Chikao Morimoto

http://www.w3.org/2001/XMLSchema#string

Eiji Takeda

http://www.w3.org/2001/XMLSchema#string

Eri Sakamoto

http://www.w3.org/2001/XMLSchema#string

Hajime Sasaki

http://www.w3.org/2001/XMLSchema#string

Hideki Fujii

http://www.w3.org/2001/XMLSchema#string

Jun Shirakawa

http://www.w3.org/2001/XMLSchema#string

Kazutaka Aoki

http://www.w3.org/2001/XMLSchema#string

Kei Ohnuma

http://www.w3.org/2001/XMLSchema#string

Kikuko Amo

http://www.w3.org/2001/XMLSchema#string

Koichiro Sato

http://www.w3.org/2001/XMLSchema#string

P2860

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets.

Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis

Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

Obesity induces a phenotypic switch in adipose tissue macrophage polarization

CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity

Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans

Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells

Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice.

P304

1246-1257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB10-1338

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49845025

http://www.w3.org/2001/XMLSchema#string

P698

21330637

http://www.w3.org/2001/XMLSchema#string

P932

3064098

http://www.w3.org/2001/XMLSchema#string